Anson Funds Management’s Inovio Pharmaceuticals INO Stock Holding History

Anson Funds Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,083	Closed	-$290K	–	181
2020 Q3	$290K	Buy	+2,083	New	+$434K	0.16%	82

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Anson Funds Management's INO Position: Q4 2020 in Review

Anson Funds Management sold out of Inovio Pharmaceuticals (INO) in Q4 2020, closing a stake of 2,083 shares — an estimated $290K sold.

Anson Funds Management first reported a position in INO in Q3 2020 and held it in 1 quarter. The position peaked at $290K in Q3 2020. 227 funds tracked by Wall St. Rank hold INO as of Q4 2020.

Anson Funds Management reported no remaining Inovio Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Anson Funds Management sold 2,083 Inovio Pharmaceuticals shares in Q4 2020, an estimated $290K.
Anson Funds Management first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Anson Funds Management's Inovio Pharmaceuticals position peaked at $290K in Q3 2020.
227 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2020.

Based on Anson Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.